Back

Future hurdles in PCSK9 - Inhibition.

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors - For the many or the few? Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Evan A Stein

Metabolic & Atherosclerosis Research Center, Cincinnati (United States of America)

4 More presentations in this session

Presentation thumbnail
PCSK9 Inhibitors - State of the art
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting
Doctor U. Kassner (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial
Professor P. Sever (London, GB)
Abstract Slides Video
Presentation thumbnail
Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation
Doctor T. Priyadechawarawong (Chiang Mai, TH)
Abstract Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors - For the many or the few?

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Medical treatment works! Contemporary implementation into clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources